A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Clinical trial NCT02333370 · COMPLETED

Trial details

NCT number: NCT02333370
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Start date: 2015-02-04
Primary completion: 2022-09-29
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.